The General Hospital Corporation

Holy Cross Hospital, Inc.

Other

The Brigham and Women's Hospital, Inc.

Imperial College of Science, Technology and Medicine

Epivax, Inc.

Imperial College London

Cytomatrix, LLC

Actx, Inc.

Innatoss Laboratories B.v.

Aperisys, Inc.

Mark C Poznansky

David T Scadden

Jeffrey A Gelfand

Tao Chen

Hajah Siti Fatimah Jaafar

Dulcie V Coleman

Pierre LeBlanc

Edward M Brown

John T Potts, Jr

Michael Rosenzweig

Mark T Ungs

Nadine Weich

Andrew David Luster

Mark J Pykett

Nicolas A F Chronos

Timothy Alan Brauns

Traci T Goodchild

Pierre R Leblanc

Ivona T Olszak

Svetlana E Korochkina

Fabrizio Vianello

Anne Searls De Groot

Jeffrey Gelfand

Natalia Papeta

Patrick Reeves

Anja Garritsen

Huabiao Chen

Dahlia Doughty

Nicholas A F Chronos

Sara Pai

Andrew T Luster

Anja Scholzen

Leonard Jeffrey Moise

Ann Elizabeth Sluder

Stephen J McCormack

Satoshi Kashiwagi

Svetlana Korochkina

Pierre Leblanc

Nicolas AF Chronos

The invention described herein relates to methods and compositions for treating cancer in a patient, or a tumor cell, by administering an effective amount of an antibody-anti-fugetactic agent complex.

Localized delivery of anti-fugetactic agent for treatment of cancer

The invention relates to fusion proteins comprising an antigen binding domain fused with a modified heat shock 70 protein. The invention further relates to methods of using the fusion proteins to induce an immune response to antigens and to treat diseases associated With antigens.

Antigen-binding fusion proteins with modified HSP70 domains

Compositions and methods for inducing a protective immune response against, to reduce a subject's risk of developing Q fever.

epitopes for T cell-targeted Q fever vaccines

The present invention relates to methods and compositions for treating human papilloma virus (HPV)-associated diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for treating immune checkpoint blockade resistant diseases using an inhibitor of CXCL12 signaling. The invention further relates to methods and compositions for enhancing the immune response against an HPV-associated disease using an inhibitor of CXCL12 signaling.

CXCR4/CXCR7 blockade and treatment of human papilloma virus-associated disease

This disclosure is directed to immune treatment of a disease (e.g., an infectious disease) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

HSP fusion protein with anti-chemorepellant agent for treatment of infectious disease

This invention is directed to the treatment of cancers, e.g., inflammatory breast cancer, with NK (natural killer) cells wherein the cells are modified ex vivo such that their ability to overcome the chemorepellant effect of a tumor is enhanced. The cells may be genetically modified ex vivo and/or modified by contacting the cells ex vivo with an anti-chemorepellant agent. This invention also provides ex vivo modified NK cells, which are modified such that they express no or substantially no CXCR4 on their cell surface, or express CXCR7, or express a chimeric antigen receptor, or combinations thereof. The invention also relates to methods for treating a patient having a tumor, e.g., inflammatory breast cancer, by administering the modified NK cells, with or without treatment with other conventional anticancer treatments, e.g., chemotherapy, radiotherapy, viral therapies, hormonal therapies, as well as other immunotherapies and anti-chemorepellant therapies.

Modified natural killer cells for the treatment of cancer

This disclosure is directed to methods of preparing dendritic cells or other CD40 bearing antigen-presenting cells and methods of treating cancer by using the dendritic cells or other antigen-presenting cells in combination with anti-chemorepellant agents. This disclosure is further directed to methods of preparing T cells and methods of treating cancer, by activated T cells optionally in combination with anti-chemorepellant agents. The antigen presenting cells of the disclosure are activated by incubation with cancer cells and fusion proteins. The T cells of the disclosures are activated by incubation with activated antigen-presenting cells that were activated by incubation with cancer cells and a fusion protein. In particular, the fusion protein comprises an antigen-binding domain, e.g., an antibody or antibody fragment, and a stress protein domain.

Ex vivo antigen-presenting cells or activated CD-positive T cells for treatment of cancer

This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.

HSP fusion protein with anti-chemorepellant agent for treatment of cancer

The invention described herein relates to methods and compositions for treating cancer in a patient or a tumor cell by administering an effective amount of an anti-fugetactic agent and an additional anti-cancer agent.

Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer

The invention generally features compositions and methods for the diagnosis, treatment, and monitoring of neoplasia in a subject, as well as methods of treatment selection.

Method of treating cervical neoplasia in patients infected with human papilloma virus

Provided herein are self-assembling pharmaceutical compositions comprising a heat shock protein fused to a biotin-binding protein, wherein the biotin-binding protein is non-covalently bound to four biotinylated components, and further wherein at least two of the four biotinylated components are not identical.

Immunotherapies employing self-assembling vaccines

CXCL12 polypeptide eluting matrices encapsulating at least one cell are described for use in the treatment of autoimmune disorders.

Eluting matrix and uses thereof

This invention provides methods and compositions for modulating movement of eukaryotic cells with migratory capacity. More specifically, the invention provides anti-fugetactic agents and methods for the use thereof in enhancing an immune response.

Antifugetactic agents for the treatment of cancers

Methods for detecting and treating cancer

Growing community of inventors

Charlestown, MA, United States of America

Mark C Poznansky